Company: CSTL
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001447362-25-000069
Chunk: 26

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-05-05
Form: 10-Q
Item: Item 1
Chunk 26
---
 profit or loss were as follows (in thousands):Three Months EndedMarch 31,20252024Interest income$3,099 $2,996 Interest expense(17)(14)Depreciation and amortization29,764 3,340 Income tax (benefit) expense(423)45 Stock-based compensation expense11,179 12,675 Changes in fair value of trading securities(1,425)— Total assets for our reportable segment were located in the United States and were $501.7 million and $531.2 million as of March 31, 2025 and December 31, 2024, respectively. Expenditures for additions to long-lived assets were $5.7 million and $8.6 million for the three months ended March 31, 2025 and 2024, respectively.

15. Subsequent Events

On April 4, 2025, the Company and its wholly owned subsidiary, Castle Narnia Way Real Estate Holding 1, LLC, entered into a Consent and First Amendment (the “Amendment”) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company. The Amendment modified certain terms of the 2024 LSA, dated March 26, 2024, including the extension of the draw period from March 31, 2025 to September 30, 2025 for our line of credit. 

21

Table of ContentsCASTLE BIOSCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(UNAUDITED)

On April 24, 2025, the Novitas LCD, Genetic Testing for Oncology: Specific Tests, that includes DecisionDx-SCC as noncovered, became effective. The final LCD was based on a proposed determination initially published in July 2023. Following a public comment and review process, the LCD recommended non-coverage for the DecisionDx-SCC test.

22

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes and other financial information included in this Quarterly Report on Form 10-Q with our audited financial statements and notes thereto as of and for the years ended December 31, 2024,and 2023 and the related Management’s Discussion and Analysis of Financial Condition and Results